Celixir Ltd. - Cell Therapy Ltd and Stem Cell Medicines Blog

Celixir is one of the most sought after UK firms which are involved in the design and development of life changing regenerative medicines while working towards common objectives with certain collaborative partnerships. With that said, let’s take a look at some of the most talked about collaborations which Celixir has secured with some of the most recognized firms and institutions in the past decade. DAIICHI SANKYO Celixir has given the license for carrying on the marketing and distributing responsibilities of their revolutionary cardiac regeneration medicine to Daiichi Sankyo on May 2016. Going by the agreement, Daiichi Sankyo will take care for the development, regulatory and commercial activities for Celixir’s immune-modulatory progenitor cells across Japanese territory. Moreover, Celixir will still be responsible for the same operations within territories across rest of the world for Celixir stem cell therapy. INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION Celixir has also for...

Celixir announces US FDA approval of the IND application for cell therapy Heartcel FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250 patients in the UK and US Stratford-upon-Avon, UK, 08 June 2018  – Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for Heartcel its immuno-modulatory progenitor (iMP) cell therapy for the treatment of adult heart failure. Celixir announced in January the approval of a clinical trial application (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency to initiate a potentially pivotal Phase II b human clinical trial with Heartcel The international trial will recruit up to 250 patients and the IND approval allows expansion to US clinical trial sites. Ajan Reginald, Chief Execu...

Celixir (formerly known as Cell Therapy Ltd.) is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need. Celixir , founded in 2009, is made up of a world-class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald . Celixir’s unique platform technology allows us to adopt an ‘off-the-shelf’ approach to deliver regenerative medicines to patients. Website : http://www.celixir.com Headquarters : Cardiff, Wales Year Founded : 2009 Company Type : Privately Held Size : 11-50 employees Specialties : regenerative medicine, cell therapies, cardiovascular medicine, cellular research, stem cells